Patient, disease, and CAR-T product characteristics
| Characteristics . | N = 54 . | % . |
|---|---|---|
| Median age, y (range) | 60 (23-81) | |
| Sex | ||
| Female | 27 | 50 |
| Male | 27 | 50 |
| Race | ||
| Caucasian | 49 | 91 |
| African American | 1 | 2 |
| Other | 4 | 7 |
| Diagnosis | ||
| DLBCL | 28 | 52 |
| FL | 3 | 5 |
| MCL | 12 | 22 |
| ALL | 2 | 4 |
| Multiple myeloma | 9 | 17 |
| Cell product | ||
| Axicabtagene ciloleucel | 23 | 42 |
| Brexucabtagene autoleucel | 9 | 24 |
| Idecabtagene vicleucel | 13 | 17 |
| Lisocabtagene maraleucel | 8 | 15 |
| Tisagenlecleucel | 1 | 2 |
| Prophylaxis before CAR-T therapies | ||
| Corticosteroids | 0 | 0 |
| Characteristics . | N = 54 . | % . |
|---|---|---|
| Median age, y (range) | 60 (23-81) | |
| Sex | ||
| Female | 27 | 50 |
| Male | 27 | 50 |
| Race | ||
| Caucasian | 49 | 91 |
| African American | 1 | 2 |
| Other | 4 | 7 |
| Diagnosis | ||
| DLBCL | 28 | 52 |
| FL | 3 | 5 |
| MCL | 12 | 22 |
| ALL | 2 | 4 |
| Multiple myeloma | 9 | 17 |
| Cell product | ||
| Axicabtagene ciloleucel | 23 | 42 |
| Brexucabtagene autoleucel | 9 | 24 |
| Idecabtagene vicleucel | 13 | 17 |
| Lisocabtagene maraleucel | 8 | 15 |
| Tisagenlecleucel | 1 | 2 |
| Prophylaxis before CAR-T therapies | ||
| Corticosteroids | 0 | 0 |
ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma.